$PACB

Van Oene Mark sold $30K of PACB

Van Oene Mark (See Remarks) sold 26,911 shares of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) at $1.13 on 2026-08-17.

Original reporting
SEC EDGAR · Van Oene Mark
Published Aug 19, 2026, 12:17 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 12:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PACB
Neutral
medium confidence
Mentioned
$PACB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PACBNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but this specific disclosure is a small open-market sale and lacks additional fundamental catalysts in the text.

02

Market read

A newly filed insider sale can cause minor, short-term sentiment noise, but it is unlikely to drive a durable repricing without accompanying company news.

03

What to watch

The text does not confirm whether the sale was part of a 10b5-1 plan (it states 'No'), but it also provides no stated reason for the sale or any concurrent operational news.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for Pacific Biosciences of California, Inc. (PACB).

Company-level read

Ticker impact

$PACBNeutralMedium confidence
Context

PACB insider Van Oene Mark sold 26,911 shares in an open-market transaction for about $30.4K, per a fresh SEC Form 4 filing.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale (not a buy), but the disclosed dollar value is relatively small and there is no 10b5-1 plan detail provided in the text.

Market effects

No sector-wide implication is disclosed; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales are often pre-planned for diversification or tax needs, so the sale may not reflect negative fundamentals.

Key entities

  • PACB

    Pacific Biosciences of California, Inc., the company whose insider transaction is disclosed.

  • Van Oene Mark

    Officer at PACB who sold 26,911 shares at $1.1300/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PACBMed

Why PacBio (PACB) Stock Is Trading Up Today

Pacific Biosciences of California (PACB) shares rose 15% to $2.88 after EpiSign and Geneyx announced a partnership using PacBio's HiFi sequencing for rare disease analysis. The stock is up 56.5% year-to-date, reaching a 52-week high. PacBio's shares are volatile, with 87 moves over 5% in the past year.

$PACBMed

Why Is PacBio (PACB) Stock Soaring Today

Pacific Biosciences (PACB) stock rose 29.7% after EpiSign launched EpiSign METRIC 5-base, a software for DNA methylation data analysis on PacBio's HiFi sequencing platform. The tool also supports Illumina and Oxford Nanopore platforms. PacBio's shares have seen high volatility, with an 86% move over the past year. The stock is up 30.4% YTD but still 9.9% below its 52-week high.

$PACBMed

PACB Stock Pops As New CEO Backs Powerful Vega Upgrade

Pacific Biosciences (PACB) stock rose 13.28% on optimism over its Vega sequencing platform upgrade. The company announced a 50% increase in data output and a 40% cost reduction per run. New CEO Mark Van Oene succeeds Christian Henry, who remains as an advisor. PACB reported $39M revenue, $44.7M net loss, and $236.9M in cash. Traders are watching for momentum driven by the upgrade and leadership change.